Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

PLoS Pathogens

Volumn 12, Issue 3, 2016, Pages

  Wagh, Kshitij ^a   Bhattacharya, Tanmoy ^a,b   Williamson, Carolyn ^c   Robles, Alex ^d   Bayne, Madeleine ^d   Garrity, Jetta ^d   Rist, Michael ^d   Rademeyer, Cecilia ^c   Yoon, Hyejin ^a   Lapedes, Alan ^a   Gao, Hongmei ^e   Greene, Kelli ^e   Louder, Mark K ^f   Kong, Rui ^f   Karim, Salim Abdool ^g,h   Burton, Dennis R ⁱ   Barouch, Dan H ^d   Nussenzweig, Michel C ^j   Mascola, John R ^f   Morris, Lynn ^h,k   Montefiori, David C ^e   Korber, Bette ^a   Seaman, Michael S ^d   more..

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b SANTA FE INSTITUTE   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

^h UNIVERSITY OF KWAZULU NATAL   (South Africa)

ⁱ SCRIPPS RESEARCH INSTITUTE   (United States)

^j ROCKEFELLER UNIVERSITY   (United States)

^k UNIVERSITY OF THE WITWATERSRAND   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY COMBINING SITE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE A; IC50; IMMUNIZATION; LUCIFERASE ASSAY; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; SCORING SYSTEM; VIRUS LOAD; VIRUS NEUTRALIZATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

ANTIBODIES, NEUTRALIZING; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84962419508     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005520     Document Type: Article

References (87)

1. Mascola JR, Montefiori DC, The role of antibodies in HIV vaccines. Annu Rev Immunol. 2010;28:413–44. doi: 10.1146/annurev-immunol-030409-10125620192810.
2. Kwong PD, Mascola JR, Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012;37(3):412–25. doi: 10.1016/j.immuni.2012.08.01222999947.
3. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC, Antibodies in HIV-1 vaccine development and therapy. Science. 2013;341(6151):1199–204. doi: 10.1126/science.124114424031012; PubMed Central PMCID: PMCPMC3970325.
4. Kwong PD, Mascola JR, Nabel GJ, Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013;13(9):693–701. doi: 10.1038/nri351623969737.
5. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One. 2010;5(1):e8805. doi: 10.1371/journal.pone.000880520098712; PubMed Central PMCID: PMCPMC2808385.
6. Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med. 2012;209(8):1469–79. doi: 10.1084/jem.2012042322826297; PubMed Central PMCID: PMCPMC3409500.
7. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458(7238):636–40. doi: 10.1038/nature0793019287373.
8. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2009;343(2):65–7. doi: 10.1016/j.jim.2008.11.01219100741; PubMed Central PMCID: PMCPMC2754789.
9. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466–70. doi: 10.1038/nature1037321849977; PubMed Central PMCID: PMCPMC3393110.
10. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285–9. doi: 10.1126/science.117874619729618; PubMed Central PMCID: PMCPMC3335270.
11. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–61. doi: 10.1126/science.118765920616233; PubMed Central PMCID: PMCPMC2965066.
12. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509(7498):55–62. doi: 10.1038/nature1303624590074; PubMed Central PMCID: PMCPMC4395007.
13. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity. 2014;40(5):657–68. doi: 10.1016/j.immuni.2014.04.00924768347; PubMed Central PMCID: PMCPMC4070425.
14. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014;515(7525):138–42. doi: 10.1038/nature1360125186731; PubMed Central PMCID: PMCPMC4224615.
15. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424):406–12. doi: 10.1038/nature1154423151583.
16. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496(7446):469–76. doi: 10.1038/nature1205323552890; PubMed Central PMCID: PMCPMC3637846.
17. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A. 2012;109(47):E3268–77. doi: 10.1073/pnas.121720710923115339; PubMed Central PMCID: PMCPMC3511153.
18. Scharf L, Scheid JF, Lee JH, West AP, Jr.Chen C, Gao H, et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014;7(3):785–95. doi: 10.1016/j.celrep.2014.04.00124767986; PubMed Central PMCID: PMCPMC4109818.
19. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333(6049):1633–7. doi: 10.1126/science.120722721764753; PubMed Central PMCID: PMCPMC3351836.
20. Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, Hsueh J, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A. 2014;111(49):17624–9. doi: 10.1073/pnas.141578911125422458; PubMed Central PMCID: PMCPMC4267403.
21. West AP, Jr.Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC, Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014;156(4):633–48. doi: 10.1016/j.cell.2014.01.05224529371; PubMed Central PMCID: PMCPMC4041625.
22. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994;266(5187):1024–7. 7973652.
23. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. 2014;88(21):12669–82. doi: 10.1128/JVI.02213-1425142607; PubMed Central PMCID: PMCPMC4248941.
24. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011;333(6049):1593–602. doi: 10.1126/science.120753221835983; PubMed Central PMCID: PMCPMC3516815.
25. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811–7. doi: 10.1126/science.119281920616231; PubMed Central PMCID: PMCPMC2981354.
26. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 2007;445(7129):732–7. doi: 10.1038/nature0558017301785; PubMed Central PMCID: PMCPMC2584968.
27. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity. 2013;39(2):245–58. doi: 10.1016/j.immuni.2013.04.01223911655; PubMed Central PMCID: PMCPMC3985390.
28. Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013;9(5):e1003342. doi: 10.1371/journal.ppat.100334223658524; PubMed Central PMCID: PMCPMC3642082.
29. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol. 2013;20(7):796–803. doi: 10.1038/nsmb.259423708606; PubMed Central PMCID: PMCPMC3823233.
30. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 2011;334(6059):1097–103. doi: 10.1126/science.121325621998254; PubMed Central PMCID: PMCPMC3280215.
31. Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med. 2014;6(236):236ra63. doi: 10.1126/scitranslmed.300810424828077; PubMed Central PMCID: PMCPMC4095976.
32. Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, et al. A new member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J Virol. 2015. doi: 10.1128/JVI.01791-1526468542.
33. Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A. 2013;110(11):4351–6. doi: 10.1073/pnas.121753711023426631; PubMed Central PMCID: PMCPMC3600498.
34. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480(7377):336–43. doi: 10.1038/nature1069622113616; PubMed Central PMCID: PMCPMC3406929.
35. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol. 2010;84(16):8098–110. doi: 10.1128/JVI.00966-1020538861; PubMed Central PMCID: PMCPMC2916520.
36. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol. 2013;20(7):804–13. doi: 10.1038/nsmb.260023708607; PubMed Central PMCID: PMCPMC4046252.
37. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A. 2010;107(25):11483–8. doi: 10.1073/pnas.100460010720534513; PubMed Central PMCID: PMCPMC2895122.
38. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity. 2005;22(2):163–73. doi: 10.1016/j.immuni.2004.12.01115723805.
39. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993;67(11):6642–7. 7692082; PubMed Central PMCID: PMCPMC238102.
40. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol. 2004;78(19):10724–37. doi: 10.1128/JVI.78.19.10724–10737.200415367639; PubMed Central PMCID: PMCPMC516390.
41. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 2001;75(22):10892–905. doi: 10.1128/JVI.75.22.10892–10905.200111602729; PubMed Central PMCID: PMCPMC114669.
42. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014;40(5):669–80. doi: 10.1016/j.immuni.2014.04.00824768348; PubMed Central PMCID: PMCPMC4057017.
43. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012;12(4):396–407. doi: 10.1016/j.chom.2012.09.00823084910; PubMed Central PMCID: PMCPMC3513329.
44. Doria-Rose NA, Joyce MG, Strategies to guide the antibody affinity maturation process. Curr Opin Virol. 2015;11:137–47. doi: 10.1016/j.coviro.2015.04.00225913818; PubMed Central PMCID: PMCPMC4456294.
45. Haynes BF, Kelsoe G, Harrison SC, Kepler TB, B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012;30(5):423–33. doi: 10.1038/nbt.219722565972; PubMed Central PMCID: PMCPMC3512202.
46. Mascola JR, Haynes BF, HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev. 2013;254(1):225–44. doi: 10.1111/imr.1207523772623; PubMed Central PMCID: PMCPMC3738265.
47. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009;15(8):951–4. doi: 10.1038/nm.197419525965; PubMed Central PMCID: PMCPMC4334439.
48. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6(2):207–10. doi: 10.1038/7231810655111.
49. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A. 2012;109(46):18921–5. doi: 10.1073/pnas.121478510923100539; PubMed Central PMCID: PMCPMC3503218.
50. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001;75(17):8340–7. 11483779; PubMed Central PMCID: PMCPMC115078.
51. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6(243):243ra88. doi: 10.1126/scitranslmed.300899224990883; PubMed Central PMCID: PMCPMC4562469.
52. Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang ZY, et al. Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol. 2015;89(11):5895–903. doi: 10.1128/JVI.00210-1525787288; PubMed Central PMCID: PMCPMC4442454.
53. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 2013;503(7475):277–80. doi: 10.1038/nature1274624172896; PubMed Central PMCID: PMCPMC4133787.
54. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503(7475):224–8. doi: 10.1038/nature1274424172905; PubMed Central PMCID: PMCPMC4017780.
55. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492(7427):118–22. doi: 10.1038/nature1160423103874; PubMed Central PMCID: PMCPMC3809838.
56. Klein F, Nogueira L, Nishimura Y, Phad G, West AP, Jr.Halper-Stromberg A, et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J Exp Med. 2014;211(12):2361–72. doi: 10.1084/jem.2014105025385756; PubMed Central PMCID: PMCPMC4235636.
57. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Jr.Buckley N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487–91. doi: 10.1038/nature1441125855300.
58. Doria-Rose NA, Louder MK, Yang Z, O'Dell S, Nason M, Schmidt SD, et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol. 2012;86(6):3393–7. doi: 10.1128/JVI.06745-1122258252; PubMed Central PMCID: PMCPMC3302320.
59. Goo L, Jalalian-Lechak Z, Richardson BA, Overbaugh J, A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection. J Virol. 2012;86(19):10857–61. doi: 10.1128/JVI.01414-1222837204; PubMed Central PMCID: PMCPMC3457273.
60. Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol. 2015;89(5):2659–71. doi: 10.1128/JVI.03136-1425520506; PubMed Central PMCID: PMCPMC4325730.
61. Barouch DH, Deeks SG, Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345(6193):169–74. doi: 10.1126/science.125551225013067; PubMed Central PMCID: PMCPMC4096716.
62. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014;158(5):989–99. doi: 10.1016/j.cell.2014.07.04325131989; PubMed Central PMCID: PMCPMC4163911.
63. Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A. 2013;110(41):16538–43. doi: 10.1073/pnas.131529511024043801; PubMed Central PMCID: PMCPMC3799352.
64. Kim AS, Leaman DP, Zwick MB, Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS Pathog. 2014;10(7):e1004271. doi: 10.1371/journal.ppat.100427125058619; PubMed Central PMCID: PMCPMC4110039.
65. McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, et al. Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathog. 2015;11(8):e1005110. doi: 10.1371/journal.ppat.100511026267277; PubMed Central PMCID: PMCPMC4534392.
66. Cimbro R, Gallant TR, Dolan MA, Guzzo C, Zhang P, Lin Y, et al. Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity. Proc Natl Acad Sci U S A. 2014;111(8):3152–7. doi: 10.1073/pnas.131471811124569807; PubMed Central PMCID: PMCPMC3939864.
67. Doores KJ, Burton DR, Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol. 2010;84(20):10510–21. doi: 10.1128/JVI.00552-1020686044; PubMed Central PMCID: PMCPMC2950566.
68. Pritchard LK, Spencer DI, Royle L, Vasiljevic S, Krumm SA, Doores KJ, et al. Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. J Virol. 2015;89(13):6952–9. doi: 10.1128/JVI.00230-1525878100; PubMed Central PMCID: PMCPMC4468474.
69. Wu X, Zhang Z, Schramm CA, Joyce MG, Kwon YD, Zhou T, et al. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1Infection. Cell. 2015;161(3):470–85. doi: 10.1016/j.cell.2015.03.00425865483.
70. Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, et al. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell. 2015;161(6):1280–92. doi: 10.1016/j.cell.2015.05.00726004070.
71. Webb NE, Montefiori DC, Lee B, Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. Nat Commun. 2015;6:8443. doi: 10.1038/ncomms944326416571; PubMed Central PMCID: PMCPMC4588098.
72. Ketas TJ, Holuigue S, Matthews K, Moore JP, Klasse PJ, Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology. 2012;422(1):22–36. doi: 10.1016/j.virol.2011.09.01922018634; PubMed Central PMCID: PMCPMC3229656.
73. Bliss CI, The Toxicity of Poisons Applied Jointly. Annals of Applied Biology. 1939;26:585–615.
74. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015. doi: 10.1111/cei.1269226332605.
75. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med. 2012;18(3):446–51. doi: 10.1038/nm.264922344296; PubMed Central PMCID: PMCPMC3296892.
76. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008;14(7):762–6. doi: 10.1038/nm177718552857; PubMed Central PMCID: PMCPMC2743464.
77. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV, Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014;158(6):1243–53. doi: 10.1016/j.cell.2014.08.02325215485; PubMed Central PMCID: PMCPMC4167398.
78. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449(7158):101–4. doi: 10.1038/nature0610617805298.
79. Montefiori DC, Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol. 2009;485:395–405. doi: 10.1007/978-1-59745-170-3_2619020839.
80. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409:131–46. doi: 10.1016/j.jim.2013.11.02224291345; PubMed Central PMCID: PMCPMC4040342.
81. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010;84(3):1439–52. doi: 10.1128/JVI.02108-0919939925; PubMed Central PMCID: PMCPMC2812321.
82. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79(16):10108–25. doi: 10.1128/JVI.79.16.10108–10125.200516051804; PubMed Central PMCID: PMCPMC1182643.
83. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514(7524):642–5. doi: 10.1038/nature1361225119033; PubMed Central PMCID: PMCPMC4433741.
84. Brent RP, Algorithms for minimization without derivatives. Englewood Cliffs, N.J.,: Prentice-Hall; 1972. xii, 195 p. p.
85. Press WH, Numerical recipes in C: the art of scientific computing. 2nd ed.Cambridge; New York: Cambridge University Press; 1992. xxvi, 994 p. p.
86. Jones E, Oliphant, T., Peterson, P. SciPy: Open source scientific tools for Python 2001- http://www.scipy.org2015.
87. Storey JD, Tibshirani R, Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100(16):9440–5. doi: 10.1073/pnas.153050910012883005; PubMed Central PMCID: PMCPMC170937.